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Aims.T oi n v e s t i g a t es e r u ml e p t i nl e v e l si nB e h c ¸et’s patients with or without ocular involvement compared with healthy subjects
and the relationship between serum leptin and uveitis activity in patients with ocular involvement. Methods. Fifty-seven patients
with Behc ¸et’s disease and 20 healthy control subjects were included in this study. While 27 patients had ocular involvement (18
had acute uveitis, 9 had inactive ocular involvement), 30 did not have ocular disease. C-reactive protein, alpha 1-antitrypsin, and
serum leptin levels were measured in all samples. Results. There was a signiﬁcant diﬀerence between the patients with Behc ¸et’s
disease and control group for both logarithm of leptin (P = .000) and logarithm of CRP (P = .031). Logarithm of leptin in non-
ocular Behc ¸et’s patients was signiﬁcantly higher compared to its level in ocular Behc ¸et’s disease and controls (P = .009). There
was a signiﬁcant diﬀerence between the patients with active ocular disease and control group (P = .03). Conclusions. Leptin might
have a possible role in the pathogenesis of Behc ¸et’s disease.
Copyright © 2007 F. Nil¨ ufer Yalc ¸ında˘ g et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Behc ¸et’s disease is a chronic, systemic inﬂammatory disor-
der aﬀecting multiple organs with a generalized vasculitis
[1]. The etiology and pathogenesis of Behc ¸et’s disease have
not been entirely enlightened. The main immunological fea-
tures of Behc ¸et’s disease consist of increased T- and B-cell re-
sponses to heat-shock proteins, increased neutrophil activity,
and alterations in cytokine levels, although the interrelation-
ships between and among these features have not been clar-
iﬁed [2]. Serum levels of neutrophil priming cytokines such
as TNF, interleukin-1β, and IL-8 are determined to be raised
in patients with Behc ¸et’s disease [3].
Leptin is a peptide hormone that regulates body weight
as well as endocrine and immune functions [4–6]. Leptin
has structural and functional similarities with members of
cytokines family [7]. The leptin receptor is homologous to
a subunit of the IL-6-type cytokine receptors [8, 9]. Leptin
shares the same signal transduction pathway with cytokines
[10].
Inlightofthefactthatleptinmightparticipateinthehost
responsetoinﬂammation,weaimedtoinvestigatechangesof
serum leptin levels in Behc ¸et’s patients with or without ocu-
lar involvement compared with healthy subjects and the rela-
tionship between serum leptin and uveitis activity in patients
withocularinvolvement.Wecomparedserumleptinchanges
with other acute phase reactants, such as CRP or alpha-1 an-
titrypsin (α1-antitrypsin).
2. MATERIAL AND METHODS
Fifty-seven patients with Behc ¸et’s disease were included in
this study. All patients included in the study met the inter-
national diagnostic criteria for Behc ¸et’s disease [11]. A com-
plete ophthalmologic examination was performed by oph-
thalmologists with an interest in Behc ¸et’s disease. While 27
patients had ocular involvement, the other 30 did not have
ocular disease. All patients with ocular involvement were
split into two groups according to the activation of eye in-
volvement to investigate the association between leptin lev-
els and ocular disease activity. Of the 27 patients who had
ocular disease, 18 suﬀered acute uveitis and 9 had inactive
ocular involvement at the time of enrollment. None of the
Behc ¸et’s patients were on systemic steroids or immunosup-
pressantagents.Twentyhealthycontrolsubjectswerealsoin-
cluded in the study. The subjects who had any systemic or
ocular disease were excluded. The subjects were matched for2 Mediators of Inﬂammation
Table 1: Patient demographics and laboratory ﬁndings in patients with ocular and nonocular Behc ¸et’s disease and controls.
Patients with Behc ¸et’s disease (BD) Control subjects
All BD patients Nonocular BD All ocular BD Active ocular BD Inactive ocular BD
Number 57 30 27 18 9 20
Age (years) 33.9 ±8.13 4 .3 ±8.93 3 .6 ±7.53 3 .3 ±93 4 .8 ±6.63 4 .7 ±8.6
BMI (kg/m2)2 5 .6 ±4.62 5 .9 ±5.42 5 .2 ±3.52 6 ±3.42 3 .7 ±3.42 3 .8 ±3.7
Log leptin (ng/mL) 1.9 ±0.42 ±0.41 .9 ±0.41 .9 ±0.41 .9 ±0.31 .7 ±0.1
α1-antitrypsin (mg/dL) 180.3 ±41.7 188.3 ±66.3 177.6 ±31.2 180.4 ±36.8 171.9 ±15.7 175.9 ±34.3
Log CRP (mg/L) 1.6 ±0.61 .6 ±0.61 .5 ±0.71 .5 ±0.71 .5 ±0.81 .2 ±0.5
age, sex, and body mass index (BMI). Informed consent was
obtained from all participants.
A venous blood sample was taken from each patient and
control subject between 8.00 a.m. and 10:00 a.m. after an
overnight fast. The blood samples were centrifugated to ob-
tain serum. All serum samples were immediately stored at
−80◦C until use.
C-reactiveprotein(CRP),α1-antitrypsin,andserumlep-
tin levels were measured in all samples. C-reactive protein
and α1-antitrypsin levels were measured by the immunotur-
bidimetric method using commercial kit (Roche Mannheim,
Germany) on P 800 autoanalyzer (Roche). Serum samples
were assayed for leptin, using enzyme-ampliﬁed sensitivity
immunoassaykit(BiosourceEuropeS.A.,Nivelles,Belgium).
Serum leptin levels were compared with those measur-
ings of other acute phase reactants, such as CRP or α1-anti-
trypsin.
2.1. Statistics
Statistical analysis was performed using SPSS 13.0 software
for Windows. As the data were not normally distributed, log-
arithmic values of CRP (log CRP) and leptin (log leptin) lev-
els were used. Statistical analysis was performed by Student
t test to compare all Behc ¸et’s patients with controls. ANOVA
and post hoc test (Tukey HSD) were used to compare ocular
Behc ¸et’s patients with nonocular Behc ¸et’s patients and con-
trols.Kruskal-WallisandMann-WhitneyU testswereusedto
c o m p a r ea c t i v eo c u l a rB e h c ¸et’s patients with inactive ocular
Behc ¸et’s patients, nonocular Behc ¸et’s patients, and controls.
Pearson’s correlation test was used for evaluating the cor-
relation between diﬀerent parameters in all groups, apart
from the group consisting of the patients with inactive eye
involvement. Spearman’s correlation analysis was used for
evaluating that group. Data were presented as mean ± SD.
Av a l u eo fP<. 05 was considered signiﬁcant.
3. RESULTS
Patientcharacteristicsandlaboratoryﬁndingsareoutlinedin
Table 1.Ofthe57patientsinthisstudy,28weremale(49.1%)
and 29 were female (50.9%). There was a signiﬁcant diﬀer-
ence between the patients with Behc ¸et’s disease and control
group for both log leptin (P = .000) and log CRP (P = .031).
L o gl e p t i ni nn o n o c u l a rB e h c ¸et’s patients was signiﬁcantly
higher compared to its level in ocular Behc ¸et’s disease and
controls (P = .009). Log leptin was not diﬀerent between pa-
tients with ocular and nonocular Behc ¸et’s disease. However,
there was a signiﬁcant diﬀerence between the patients with
active ocular Behc ¸et’s disease and control group (P = .03).
InpatientswithBehc ¸et’sdisease,logleptinwascorrelated
with BMI (r = .44, P = .001), and α1-antitrypsin was cor-
related with log CRP (r = .61, P = .000). On the other
hand, there was no signiﬁcant correlation between log lep-
tin and α1-antitrypsin or log CRP. In patients with nonocu-
lar Behc ¸et’s disease, α1-antitrypsin was correlated with log
CRP (r = .56, P = .002), and log leptin was correlated
with BMI (r = .052, P = .004). In patients with ocular
Behc ¸et’s disease, α1-antitrypsin was correlated with log CRP
(r = .73, P = .000). In patients with active ocular Behc ¸et’s
disease, α1-antitrypsin was correlated with log CRP (r = .79,
P = .000). In patients with inactive ocular Behc ¸et’s disease,
log leptin was correlated with BMI (r = .86, P = .007),
and α1-antitrypsin was correlated with log CRP (r = .81,
P = .014). In control group, there was no signiﬁcant corre-
lation between log leptin and α1-antitrypsin or BMI and log
CRP.
4. DISCUSSION
Leptin is primarily produced by adipose tissue. Leptin lev-
els in the systemic circulation are controlled by a variety of
factors, especially food intakeand the endocrine system [12].
Theinnateimmunesystemalsoparticipatesintheregulation
of leptin production.
In experimental animals, leptin levels are acutely in-
creased after administration of the inﬂammatory stimulus
such as lipopolysaccharide (LPS) and turpentine, and proin-
ﬂammatorycytokines such as tumor necrosis factor-α (TNF-
α) and interleukin-1 (IL-1) [5, 13]. The kinetics of leptin-
production during infectious and inﬂammatory processes is
similar to that of cytokine induction [14].
Data obtained in human studies regarding the regulation
of leptin expression in response to infection and inﬂamma-
tionarevaried.TheadministrationofIL-1β orTNF-αresults
in increased serum leptin levels in healthy subjects [15, 16].
However, no increase in serum leptin levels was found after
LPS injection to humans [17]. Leptin concentrations were
found to be elevated during an acute inﬂammatory stimu-
l u ss u c ha sm a j o rs u r g e r y[ 18]. Nevertheless, in the chronic
phase of inﬂammatory diseases such as rheumatoid arthritisF. Nil¨ ufer Yalc ¸ında˘ ge ta l . 3
and inﬂammatory bowel disease, inﬂammation-associated
leptin peaks were not observed [19, 20].
Although the etiology and pathogenesis of Behc ¸et’s dis-
ease are not clear, increased serum levels of inﬂammatory cy-
tokines have been established to correlate with Behc ¸et’s dis-
ease activity [3–21]. A correlation between leptin levels and
disease activity in patients with Behc ¸et’s disease has been re-
ported [22]. Leptin levels in 35 patients with Behc ¸et’s disease
were also found to be higher than in healthy controls in that
study [22]. In another study, 28 males with ocular Behc ¸et’s
disease were compared with 15 healthy controls, and serum
levels of leptin were not signiﬁcantly diﬀerent between the
groups [23]. In that study, leptin levels were compared be-
tween patients with ocular Behc ¸et’s disease and healthy sub-
jects; whereas, we compared leptin levels between the groups
composed of Behc ¸et’s patients with and without ocular in-
volvement and healthy subjects. In our study, patients with
Behc ¸et’s disease with or without ocular involvement were
found to have higher serum leptin and CRP levels compared
according to age-, sex-, and BMI-matched controls. How-
ever,inBehc ¸et’spatientswithocularinvolvement,serumlep-
tin concentrations were not signiﬁcantly diﬀerent from those
in Behc ¸et’s patients without ocular involvement in our study.
The results of our study also demonstrated that the mean
serum leptin levels were signiﬁcantly increased in patients
with active uveitis compared to control subjects.
Becauseserumleptinlevelsarecloselyassociatedwiththe
amount of body fat and diﬀer between males and females,
BMI- and sex-matched subjects were enrolled in the groups.
The subjects were on systemic steroids or immunosuppres-
sive agents were not included in the study to avoid the possi-
ble eﬀects of these agents on the serum leptin levels.
In conclusion, the higher serum leptin levels in patients
with Behc ¸et’s disease compared to control subjects in the
present study might be attributed to a possible role for leptin
in the pathogenesis of Behc ¸et’s disease. Elevated serum leptin
level does not seem to be a risk factor in ocular involvement.
However, there might be a correlation between leptin levels
and uveitis activity. Future studies would be useful to clarify
the potential inﬂuence of leptin in Behc ¸et’s disease.
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